Sign up to see all 5.
Sign up to see all 5.
No insider has filed a notice of proposed sale (Form 144) for Jade Biosciences, Inc. in the last 12 months.
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
F
FMR LLC
|
9.1M | 14.35% | +2.0M (+28.8%) | 2025 | 0.0% | |
|
Shares held by quarter
Peak holding9.1M (Q2'26)
Change over 8 quarters+9.1M
Share of the company14.350%
|
||||||
|
JT
Jupiter Topco LLC
|
6.3M | 9.86% | NEW | Q2 '26 | 0.1% | |
|
Shares held by quarter
Peak holding6.3M (Q2'26)
Change over 8 quarters+6.3M
Share of the company9.860%
|
||||||
28 more super investors behind a free account
See every manager holding Jade Biosciences, Inc., how their position has changed, and how long they've held it.
Sign up free| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
VT
Vanguard Index Funds
|
$37.8M | 1.7M | 2.67% | 0.00% | June 30, 2026 |
|
SS
SPDR Series Trust
|
$34.1M | 1.5M | 2.41% | 0.32% | June 30, 2026 |
23 more funds behind a free account
See every fund holding Jade Biosciences, Inc. and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
PE
Peter Evan Harwin
5%+ holder
13D · 20.0%
|
14.1M | 22.12% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
TK
Tomas Kiselak
5%+ holder
13D · 20.0%
|
14.1M | 22.11% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
11 more holders behind a free account
See every insider and 5%+ holder of Jade Biosciences, Inc..
Sign up freeLoading...